Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an …
…, M Okada, K Yoshimori, I Nakachi… - The Lancet …, 2019 - thelancet.com
Background Resistance to first-generation or second-generation EGFR tyrosine kinase
inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small-cell …
inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small-cell …
[HTML][HTML] Comparison of rapid antigen tests for COVID-19
…, Y Sakai-Tagawa, M Koga, O Akasaka, I Nakachi… - Viruses, 2020 - mdpi.com
Reverse transcription-quantitative PCR (RT-qPCR)-based tests are widely used to diagnose
coronavirus disease 2019 (COVID-19). As a result that these tests cannot be done in local …
coronavirus disease 2019 (COVID-19). As a result that these tests cannot be done in local …
[HTML][HTML] Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
…, M Ito, O Akasaka, M Nakamura, I Nakachi… - …, 2021 - thelancet.com
Background To develop an effective vaccine against a novel viral pathogen, it is important
to understand the longitudinal antibody responses against its first infection. Here we …
to understand the longitudinal antibody responses against its first infection. Here we …
Characterization of a new SARS-CoV-2 variant that emerged in Brazil
…, O Akasaka, M Nakamura, I Nakachi… - Proceedings of the …, 2021 - National Acad Sciences
The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
plays a key role in viral infectivity. It is also the major antigen stimulating the host's protective …
plays a key role in viral infectivity. It is also the major antigen stimulating the host's protective …
[HTML][HTML] Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells
…, K Soejima, H Yasuda, I Kawada, I Nakachi… - Cancer cell …, 2008 - Springer
Background Alterations in the processing of the genetic information in carcinogenesis result
from stable genetic mutations or epigenetic modifications. It is becoming clear that …
from stable genetic mutations or epigenetic modifications. It is becoming clear that …
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival …
…, M Okada, K Yoshimori, I Nakachi… - The Lancet …, 2022 - thelancet.com
Background Bevacizumab is a promising candidate for combination treatment with epidermal
growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could improve …
growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could improve …
The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer
…, K Yoh, T Kato, K Nishino, A Nakamura, I Nakachi… - Nature, 2021 - nature.com
Lung cancer is one of the most aggressive tumour types. Targeted therapies stratified by
oncogenic drivers have substantially improved therapeutic outcomes in patients with non-small-…
oncogenic drivers have substantially improved therapeutic outcomes in patients with non-small-…
Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution
Limited knowledge exists on immune markers associated with disease severity or recovery
in patients with coronavirus disease 2019 (COVID-19). Here, we elucidated longitudinal …
in patients with coronavirus disease 2019 (COVID-19). Here, we elucidated longitudinal …
Exhaustion of airway basal progenitor cells in early and established chronic obstructive pulmonary disease
M Ghosh, YE Miller, I Nakachi, JB Kwon… - American journal of …, 2018 - atsjournals.org
Rationale: Up to 40% of smokers develop chronic obstructive pulmonary disease (COPD)
over a period that spans decades. Despite the importance of COPD, much remains to be …
over a period that spans decades. Despite the importance of COPD, much remains to be …
NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
…, O Yamaguchi, M Okada, K Yoshimori, I Nakachi… - 2020 - ascopubs.org
9506 Background: In NEJ026, a phase III trial comparing bevacizumab plus erlotinib (BE) to
erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we …
erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we …